CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians

Carcinogenesis

Volumn 29, Issue 9, 2008, Pages 1751-1757

  Beuten, Joke ^a   Gelfond, Jonathan A L ^b   Byrne, John J ^a   Balic, Ivana ^a   Crandall, Analisa C ^a   Johnson Pais, Teresa L ^a   Thompson, Ian M ^b   Price, Douglas K ^c   Leach, Robin J ^a,b  

^a University of Texas Health Science Center at San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1B1;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HAPLOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 51849141746     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm300     Document Type: Article

References (47)

1. Jemal,A. et al. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66.
2. Lichtenstein,P. et al. (2000) Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med., 343, 78-85.
3. Conlon,E.M. et al. (2003) Oligogenic segregation analysis of hereditary prostate cancer pedigrees: Evidence for multiple loci affecting age at onset. Int. J. Cancer, 105, 630-635.
4. Hsing,A.W. et al. (2001) Trends and patterns of prostate cancer: what do they suggest? Epidemiol. Rev., 23, 3-13.
5. Makridakis,N.M. et al. (2001) Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol. Rev., 23 24-29.
6. Pollak,M. (2001) Insulin-like growth factors and prostate cancer. Epidemiol. Rev., 23, 59-66.
7. Cheung,Y.L. et al. (1999) Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. Cancer Lett., 139, 199-205.
8. Agundez,J.A. (2004) Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab., 5, 211-224.
9. Hayes,C.L. et al. (1996) 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl Acad. Sci. USA, 93, 9776-9781.
10. Spink,D.C. et al. (1992) 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: A comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch. Biochem. Biophys., 293, 342-348.
11. Crespi,C.L. et al. (1997) Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: Substrate specificity with model substrates and promutagens. Mutagenesis, 12, 83-89.
12. Sutter,T.R. et al. (1994) Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem., 269, 13092-13099.
13. Tang,Y.M. et al. (1996) Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J. Biol. Chem., 271, 28324-28330.
14. Murray,G.I. et al. (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res., 57, 3026-3031.
15. McFadyen,M.C. et al. (1999) Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J. Histochem. Cytochem., 47, 1457-1464.
16. McFadyen,M.C. et al. (2001) Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br. J. Cancer, 85, 242-246.
17. Carnell,D.M. et al. (2004) Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int. J. Radiat. Oncol. Biol. Phys., 58, 500-509.
18. Rochat,B. et al. (2001) Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Ther., 296, 537-541.
19. Cavalieri,E.L. et al. (2002) Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: Implications for estrogen-induced initiation of prostate cancer. Carcinogenesis, 23, 329-333.
20. Williams,J.A. et al. (2000) Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis, 21, 1683-1689.
21. Buters,J.T. et al. (1999) Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[α]anthracene-induced lymphomas. Proc. Natl Acad. Sci. USA, 96, 1977-1982.
22. McGrath,M. et al. (2004) Cytochrome P450 1B1 and catechol-O methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis, 25, 559-565.
23. Sissung,T.M. et al. (2006) Pharmacogenetics and regulation of human cytochrome P450 1B1: Implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol. Cancer Res., 4, 135-150.
24. Shimada,T. et al. (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis, 20, 1607-1613.
25. Hanna,I.H. et al. (2000) Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res., 60 3440-3444.
26. Li,D.N. et al. (2000) Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics, 10, 343-353.
27. Tang,Y.M. et al. (2000) Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics, 10, 761-766.
28. Fukatsu,T. et al. (2004) Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res., 24, 2431-2437.
29. Tanaka,Y. et al. (2002) Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem. Biophys. Res. Commun., 296, 820-826.
30. Cicek,M.S. et al. (2005) Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol. Biomarkers Prev., 14, 2173-2177.
31. Chang,B.L. et al. (2003) Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br. J. Cancer, 89, 1524-1529.
32. Hazuda,H.P. et al. (1986) A comparison of three indicators for identifying Mexican Americans in epidemiologic research. Methodological findings from the San Antonio Heart Study. Am. J. Epidemiol., 123, 96-112.
33. O'Neill,J.P. et al. (1998) Mutations that alter RNA splicing of the human HPRT gene: A review of the spectrum. Mutat. Res., 411 179-214.
34. Gotoda,T. et al. (1997) Skipping of exon 14 and possible instability of both the mRNA and the resultant truncated protein underlie a common cholesteryl ester transfer protein deficiency in Japan. Arterioscler. Thromb. Vasc. Biol., 17, 1376-1381.
35. Duan,J. et al. (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet., 12, 205-216.
36. French,B. et al. (2006) Simple estimates of haplotype relative risks in casecontrol data. Genet. Epidemiol., 30, 485-494.
37. Barrett,J.C. et al. (2005) Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
38. Gabriel,S.B. et al. (2002) The structure of haplotype blocks in the human genome. Science, 296, 2225-2229.
39. Risbridger,G.P. et al. (2003) Oestrogens and prostate cancer. Endocr. Relat. Cancer, 10, 187-191.
40. Chaib,H. et al. (2001) Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia, 3, 43-52.
41. Hwang,D.Y. et al. (2003) Differential expression of the tetracycline-controlled transactivator-driven human CYP1B1 gene in double-transgenic mice is due to androgens: Application for detecting androgens and antiandrogens. Arch. Biochem. Biophys., 415, 137-145.
42. Merrill,R.M. et al. (2000) Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology, 55, 730-735.
43. Thompson,I. et al. (2001) Association of African-American ethnic background with survival in men with metastatic prostate cancer. J. Natl Cancer Inst., 93, 219-225.
44. Aklillu,E. et al. (2002) Functional analysis of six different polymorphic CYP1B1enzyme variants found in an Ethiopian population. Mol. Pharmacol., 61, 586-594.
45. McLellan,R.A. et al. (2000) Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch. Biochem. Biophys., 378, 175-181.
46. Mammen,J.S. et al. (2003) Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[α]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis, 24 1247-1255.
47. Bandiera,S. et al. (2005) Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol. Pharmacol., 67, 435-443.